Welcome to our dedicated page for Trinity Biotech news (Ticker: TRIB), a resource for investors and traders seeking the latest updates and insights on Trinity Biotech stock.
Trinity Biotech plc reports developments across its commercial-stage diagnostics and health technology business, including clinical laboratory products, point-of-care testing, diabetes management solutions, and wearable biosensor development. Its updates frequently cover the Premier Hb9210 HbA1c laboratory blood glucose monitoring platform, TrinScreen HIV testing, and the CGM+ continuous glucose monitoring program.
Company news also addresses specialty diagnostics initiatives such as EpiCapture prostate cancer testing and autoimmune biomarker work supported by its New York State Department of Health-certified reference laboratory. Other recurring topics include commercial operations in North America, manufacturing and cost-control actions under its Comprehensive Transformation Plan, ADS-based financing arrangements, trading updates, and Nasdaq listing-status notices.
Trinity Biotech (TRIB) announced that its Trinovium subsidiary has signed a contract with Red Team Investments (RTI) to supply advanced liquid cooling fluids and analytical systems for a U.S. commercial pilot in AI and high-performance computing modular data centers.
The agreement makes RTI a paid commercial pilot customer and establishes a framework to co-develop and deploy direct-to-chip liquid cooling for AI, HPC and modular data center applications. Trinovium expects to gain real-world operating data to validate and refine its cooling fluids and monitoring platform. The collaboration initially focuses on integration planning, product testing and pilot deployment, followed by analysis of performance data and potential broader commercialization.
Trinity Biotech (Nasdaq: TRIB) issued a broad update on its diagnostics business, operational transformation and Nasdaq listing status. The company appointed Jordi Romero as Head of Commercial Operations – Europe to strengthen sales execution in haemoglobin diagnostics and support profitable growth across European and international markets.
Trinity reported ongoing rollout of its upgraded high-capacity HbA1c column system for the Premier Hb9210™ analyser, now completed in three major international markets, offering up to four times testing capacity and reduced calibration needs. The operational transformation continues, with approximately 9 million TrinScreen HIV tests manufactured under an outsourced model and Uni-Gold™ HIV production now also commenced externally.
In its pipeline, Trinity secured a new European patent for blood pressure-related metrics in its PrePsia™ preeclampsia prediction platform, bringing total PrePsia™-related patents in Europe and the U.S. to nine and supporting future commercialization via its New York reference lab. The company also disclosed that it did not regain compliance with Nasdaq’s $15 million market value of publicly held shares requirement by August 18, 2026, received a staff determination letter, and plans to request a hearing, which would stay any suspension or delisting action while a panel considers a possible extension to as late as February 24, 2027.
Trinity Biotech (NASDAQ: TRIB) announced that its Trinovium subsidiary has agreed to a strategic collaboration with Echelon Data Centres, a hyperscale data center owner, developer and operator, to co-develop next-generation high-performance liquid cooling solutions for AI and high‑density computing infrastructure.
The collaboration will combine Trinovium’s ultra‑high‑purity fluid manufacturing and analytical technologies with Echelon’s large hyperscale portfolio, which includes more than 700 MW under development, over 1.4 GW of secured capacity and more than 4 million m² of data center space. Initial work will focus on direct‑to‑chip cooling fluids, thermal management systems and modular solutions optimized for AI and high‑performance computing.
According to Trinity Biotech, Trinovium has already developed an initial direct‑to‑chip liquid cooling formulation built around ultra‑high‑purity aqueous chemistry, corrosion inhibition and healthcare‑level consistency and traceability. Trinovium is also advancing a fluid health and system intelligence platform intended to monitor corrosion, particulates and microbial growth, aiming to create a data‑driven, recurring‑revenue service layer in the growing data center liquid cooling market, projected to rise from $4 billion in 2026 to $27 billion by 2033.
Trinity Biotech (Nasdaq: TRIB) announced an additional approximately $7.0 million investment from funds managed by Perceptive Advisors, its largest financial investor and primary lender. The company also confirmed it has regained compliance with Nasdaq’s minimum bid price requirement under Listing Rule 5450(a)(1).
According to Trinity Biotech, the financing strengthens liquidity to support strategic initiatives, including its CGM+ continuous glucose monitoring platform, broader diagnostics and metabolic health business, and Trinovium’s liquid cooling solutions for AI data centers. The $7.0 million package includes about $2.5 million of new debt funding and roughly $4.5 million of capitalised interest via an amendment to existing financing arrangements.
Nasdaq confirmed compliance on August 7, 2026, after the company’s ADSs closed at or above $1.00 for 10 consecutive business days from July 24 through August 6, 2026. Trinity Biotech reported preliminary Q2 2026 revenues of approximately $10.5 million, described as broadly consistent with Q1 2026, as it moves into the latter stages of its operational and strategic repositioning.
Trinity Biotech (NASDAQ: TRIB) announced a strategic collaboration with Latch Medical to combine Trinity Biotech's AI-native CGM+ wearable biosensor platform with Latch Medical's hollow microneedle intradermal drug delivery technology, Pharma Latch™, to evaluate precision therapeutic solutions for diabetes, obesity and other metabolic conditions.
The partners plan to use real-time metabolic data from CGM+ to help guide and optimize injectable therapy delivery, aiming for more personalized, responsive treatment approaches. Trinity Biotech has also agreed in principle to make a strategic equity investment in Latch Medical, supported by its largest financial investor, Perceptive Advisors. The collaboration is intended to expand CGM+ beyond monitoring into an integrated metabolic health platform that combines continuous sensing, AI-driven insights and precision drug delivery, and builds on Trinity Biotech's recently announced positive CGM+ clinical trial data on nocturnal compression lows.
Trinity Biotech (Nasdaq: TRIB) plans to change its American depositary share (ADS) ratio from 1 ADS representing 20 Class A ordinary shares to 1 ADS representing 600 Class A ordinary shares, effectively a 1‑for‑30 reverse ADS split for ADS holders.
The change is intended to help regain compliance with Nasdaq’s $1.00 minimum bid price requirement and to support investment from investors who prefer securities trading above $5.00. There is no change to the underlying Class A ordinary shares. The new ratio is expected to become effective at the start of Nasdaq trading on July 24, 2026.
ADS holders must mandatorily surrender every 30 existing ADSs to The Bank of New York Mellon to receive 1 new ADS. No fractional new ADSs will be issued; fractional entitlements will be aggregated, sold by the depositary, and net cash proceeds distributed to affected ADS holders. The ADSs will continue to trade on Nasdaq under the symbol TRIB, and the company expects the ADS price to increase proportionally, while giving no assurance that it will equal or exceed 30 times the prior price.
Trinity Biotech (Nasdaq: TRIB) reported new clinical data for its next-generation CGM+ wearable biosensor platform. Analysis of about 5,000 hours of pre-pivotal clinical wear data shows purpose-built capability to distinguish nocturnal compression-related false lows from true blood glucose lows.
The multi-sensor CGM+ system combines glucose with additional physiological signals and AI-driven analytics to add context beyond glucose-only CGM. According to Trinity Biotech, this supports differentiation in the approximately $15 billion global CGM market as CGM+ advances toward pivotal trial and regulatory submission.
Trinity Biotech (Nasdaq: TRIB) announced that its AI data center liquid cooling subsidiary Trinovium has secured Silver Membership in the Open Compute Project (OCP), providing direct engagement with leading hyperscale operators and technology firms.
According to Trinity Biotech, OCP participation should support product development, accreditation, hyperscale market access, and a capital-efficient entry into a liquid cooling market projected to grow from $4B in 2026 to $27B by 2033.
Trinity Biotech (Nasdaq: TRIB) announced on June 29, 2026 that it has given formal notice to terminate its Standby Equity Purchase Agreement (SEPA) with YA II PN, an affiliate of Yorkville Advisors Global, ending its related equity line of credit facility.
The company does not intend to use the SEPA further, and indicates that the termination aligns with its current financing strategy.
Trinity Biotech (NASDAQ:TRIB) launched Trinovium, a subsidiary focused on advanced liquid cooling fluids and intelligence systems for AI and high‑performance computing data centers.
Trinovium targets the data center liquid cooling market, projected to grow from $4 billion in 2026 to $27 billion by 2033 (31.5% CAGR), leveraging Trinity’s US/EU high‑purity fluid manufacturing and analytics. Initial products include a direct‑to‑chip coolant built around ultra‑high purity, corrosion protection, and healthcare‑grade consistency, plus a planned fluid health monitoring platform. Trinity continues to commercialize its FDA 510(k)‑cleared diabetes and hemoglobin analyzers, WHO‑prequalified HIV tests, and develop its CGM+ continuous glucose monitoring solution.